• Transactions of the Korean Society of Mechanical Engineers B
• /
• v.38 no.12
• /
• pp.971-974
• /
• 2014

A ventricular assist device (VAD) is used for bridge to heart transplantation and heart diseases. Knowing the status of a pneumatic pulsatile VAD when implanting it into the body is important: when the velocity of blood flow through the VAD is slow, a thrombus may occur, and thrombosis can be fatal to a patient. In order to determine the state of a VAD, various sensors need to be implanted. Because this introduces the risk of infection and difficulties with sensor management, we developed a method for estimating the state of a VAD indirectly via the pressure in an air tube that can be measured in vitro. We compared the measured values to in vitro experimental results. The estimated and measured values showed some errors, but the accuracy can be improved by refining the estimation process to minimize the risk of infection.

• Journal of Chest Surgery
• /
• v.30 no.3
• /
• pp.247-252
• /
• 1997

Ten acute and chronic in vivo studies were utilized to develop a pneumatic ventricular assist device (VAD) as a bridge to heart transplantation or a circulatory assist device for patients with end-stage heart disease or poor myocardial funct on after cardiac surgery. Two sizes of blood pump of 70cc for adult patients and 34cc for pediatric patients were implanted in the animals. Ventricle of the blood pump was made from the polyurethaae to enhance antithrombogenecity. The VAD was implanted between the left atrium and the descending aorta. Average flow rate was 2.38 L/min for adult and 0.41 L/min for pediatric VAD at the rate of 60 bum. The duration of support ranged from 1 to 26 hours. The most frequent complication was bleeding. Main causes of death were heart failure and respiratory failure. The device function was good for short term use. Studies to date suggest that, with further refinement, a reliable long term VAD that will have clinical application can be developed.

• Transactions of the Korean Society of Mechanical Engineers B
• /
• v.35 no.11
• /
• pp.1191-1198
• /
• 2011

The use of a ventricular assist device (VAD) can raise the one-year survival rate without cardiac transplantation from 25% to 52%. However, malfunction of the VAD system causes 6% of VAD patients' deaths, which could possibly be avoided through the development of new VADs in which VAD malfunctions do not affect the patient's heart movement or hemodynamic state. A conventional VAD has an impeller or vane for propelling blood that can allow blood to regurgitate when the propelling force is weaker than the aortic pressure. In this paper, we developed a new pulsatile conduit-shaped VAD that has two valves. This device removes the possibility of blood regurgitation and has a small stationary area even when the pumping force is extremely weak. We estimated the characteristics of the device by measuring the outflow and the pressure of the pump in in-vitro and in-vivo experiments.

• Journal of Chest Surgery
• /
• v.27 no.5
• /
• pp.390-393
• /
• 1994

의료기술의 발달로 오늘날의 개심술은 대부분 성공적으로 시행되고 있지만 극히 일부분은 아직도 개심술후 심한 심실기능의 저하로 사망하는 겨우가 있다. 1960년대 중반 Spencer와 DeBakey에 의해 개심술후 심한 심실기능이 저하된 환자에게 심실보조장치를 이용하여 성공적으로 치험한 이후로 많은 발전을 거듭해 왔다. 저자들은 4개월 (6.5Kg)된 남아에서 개심술후 심한 저심박출증으로 인공심폐기의 제거를 못하여 좌심실 보조장치(Centrifugal Biopump)를 사용하여 성공적으로 치험하였기에 보고하는 바이다.

• Journal of Biomedical Engineering Research
• /
• v.23 no.1
• /
• pp.33-38
• /
• 2002

A Ventricular Assist Device(YAD) is used to support the injured natural heart So. when considering a control algorithm for YAD. it is important to reduce a natural heart's load to enhance its recovery condition. To reduce natural heart's load, a counterpulsation algorithm is used commonly. In this study, we developed a counterpulsation control algorithm for moving-actuator type VAD and tested its usefulness using in vitro MOCK circulatory system. To notice a natural heart's Pumping status, electrocardiogram(ECG) signal was used and as a result of test. the counterpulsation effect between YAD and a natural heart was occurred and Automatic Control Mode Transition was occurred properly.

• Journal of Chest Surgery
• /
• v.33 no.11
• /
• pp.906-909
• /
• 2000

심폐바이패스를 사용하지 않고 심장박동 상태에서 시행하는 관상동맥 우회수술은 심 비대와 좌심실 기능저하가 동반된 협증심 환자에서는 심장 뒤쪽에 위치한 관상동맥에 대한 접근이 어렵고 수술 중 혈역학적으로 불안정하여 시행하기에 어려운 경우가 많다. 우심실 보조장치 하의 심장박동 상태에서 시행하는 관상동맥 우회수술은 대동맥의 삽관을 피하고, 심폐바이패스의 합병증을 줄일 수 있으며, 심장 뒤쪽에 위치한 혈관의 문합시에도 안정된 혈역학적 상태를 유지 할 수 있어 고위험군 환자에게 도움을 줄 수 있다. 좌심실 기능저하와 심 비대가 동반된 환자에서 우심실 보조장치 하의 심장박동 상태에서 시행한 관상동맥 우회수술을 2례 시행하여 좋은 결과를 얻어 보고하고자 한다.

• Proceedings of the KTCVS Conference
• /
• 1995.10a
• /
• pp.44-44
• /
• 1995

• Transactions of the Korean Society of Mechanical Engineers B
• /
• v.35 no.11
• /
• pp.1205-1211
• /
• 2011

In this paper, we developed a pacemaker that can increase the efficacy of a left ventricular assist device (LVAD) and increase the survival rate for patients suffering end-stage heart failure. Because LVAD patients can experience arrhythmia, the pacemaker incorporated into the LVAD has the important role of sustaining sufficient blood circulation during arrhythmia. The electrode of the pacemaker is located at the apex of the left ventricle, where the VAD's inlet cannula is connected. This is efficient placement, in that the electrode can transmit electrical stimulation directly to the Purkinje fibers of the myocardium. The pacemaker can change the stimulation rate from 0 bpm to 191.4 bpm when a button is pressed on the external control module, and the pacemaker normally stimulates the heart at 60 bpm with 0.25 J of energy. We performed animal experiments to evaluate the performance and reliability of the combination of the LVAD and pacemaker. At pacemaker stimulation rates of 86.4 bpm, 100.2 bpm, 126.6 bpm, we recorded the ECGs, aortic pressures, and flow rates to analyze the heart loads.

• Journal of Chest Surgery
• /
• v.29 no.7
• /
• pp.689-699
• /
• 1996

An animal experiment was designed for the evaluation of in vivo performance of the newly developed electrohydraulic type ventricular assist device and its influence on the left ventricular function during pal- satile left ventricular assist. Eight adult sheep were incorporated into the study and data were collected from seven sheep. Total as- sist time ranged from 69 minutes to 7 days. The performance of the device was satisfactory both in asyn- chr nous and synchronous mode within the range of given native heart rate. More than 4 liters of device output could be reached within the range of normal left atral pressure without development of negative pressure in the left atrium. Moderate to severe degree of hemolysis was noted as evidenced by significant increase of plasma free hemoglobin level after 3 days of left ventricular support along with the presence of the small amount of thrombi around the floating disc type polymer valve apparatus reflecting that further study and refinement of the device need to be done in regard of biocompatibility and thromboresistance. The hemodynamics showed increase in heart rate (p < 0.05), cardiac output and left ventricular minute work (p < 0.05) after placement of the device at the flow rate of 2.0∼2.5 Llmin. The left atrial pressure, left ventricular pressure and LV dpldt were decreased after the device placement(p < 0.05). The endocardial viability ratio and oxygen contents of the mixed ven us blood and coronary venous blood were all increased (p < 0.05) after the device placement suggesting effective unloading of the left ventricle was accomplished. The myocardial perfusion was thought improved in synchronous counterpulsation as suggested by sig- nificant increase in endocardial viability ratio and coronary venous blood oxygen content in synchronous assist mode comparing with asynchronous mode.

• Journal of Chest Surgery
• /
• v.29 no.11
• /
• pp.1218-1222
• /
• 1996

The reported incidence of postcardiotomy cardiogenic shock not responding to conventional therapy is still 0.1 to 0.8%. For this group of patients, more aggressive form of circulatory support must be employed. Centrifugal pumps are a ventricular assist device most commonly used on this purpose, due to low cost and easy availability. Currently, however, clinical experience of centrifugal pumps as a ventricular assist device is rarely reported in Korea. From January 1992 to January 1996, 2986 patients underwent cardiac operations on cardiopulmonary bypass at Seoul National University Hospital. Refractory postcardiotomy cardiac failure requring ventricular support with a Biomedicus centrifugal pump developed in ten of these patients. There were eight men and two women, ranged in age from nine years to 77 years with a mean of 50$\pm$20 years. The primary surgical procedures consisted of isolated coronary revascularization in four patients, combined coronary revascularization and aortic valve replacement in two, aortic dissection repair in two, pulmonary embolectomy in one, and heart transplantation in one. Of the ten patients, five had left ventricular assistance, one had right ventricular assistance, and four had biventricular assistance. Duration of ventricular assistance ranged from 24 to 175 hours, with a mean of 76$\pm$51 hours. Seven patients were weaned from ventricular assistance, and four of them discharged. The causes of death for nonsurvivors were progressive cardiac failure in two patients and multiorgan failure, intractable ventricular fibrillation, irreversible brain injury, and mechanical problem, respectively, in the other four. Survival was not predicted by time on cardiopulmonary bypass, aortic cross-clamp time, or duration of ventricular support. Major complications included bleeding(7), renal failure(6), infection(3) and neurologic complication(2). These results indicate that a centrifugal pump can provide reasonably satisfactory short-term circulatory support.